SCHEMBL1715037

SCHEMBL1715037

CC(=O)Nc1nc(C)c(S(=O)(=O)NCCCON)s1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RORA P35398 1/20 0.44
RORC P51449 1/20 0.44
RORB Q92753 1/20 0.44
PIK3CD O00329 7/20 0.43
PIK3CG P48736 12/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
PIK3CA P42336 5/20 0.41
PIK3CB P42338 4/20 0.41
PIK3C3 Q8NEB9 2/20 0.41
PI4KB Q9UBF8 2/20 0.41
PIK3C2A O00443 1/20 0.41
PIK3C2B O00750 1/20 0.41
PI4KA P42356 1/20 0.41
PRKDC P78527 1/20 0.41
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1715514 0.93 RORA (0.46) RORARORCRORBPIK3CDPIK3CG
SCHEMBL6258673 0.85 RORA (0.42) RORARORCRORBPIK3CDPIK3CG
SCHEMBL1939226 0.82 PIK3CG (0.56) RORARORCRORBPIK3CDPIK3CG
SCHEMBL12461333 0.82 RORA (0.49) RORARORCRORBPIK3CDPIK3CG
SCHEMBL6260692 0.80 RORA (0.43) RORARORCRORBPIK3CDPIK3CG
SCHEMBL12201045 0.79 RORA (0.51) RORARORCRORBPIK3CDPIK3CG
SCHEMBL1939916 0.79 RORA (0.49) RORARORCRORBPIK3CDPIK3CG
SCHEMBL12203600 0.79 RORA (0.49) RORARORCRORBPIK3CDPIK3CG
SCHEMBL6101006 0.78 RORA (0.50) RORARORCRORBPIK3CDPIK3CG
SCHEMBL6019728 0.78 RORA (0.46) RORARORCRORBPIK3CDPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US claimed
JP-2007513098-A 2007-05-24 JP claimed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO claimed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 RORA 799/4885RORC 2101/4885RORB 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.